Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 2
---
ary Share

Up to 4,422,604 American Depositary Shares Representing 442,260,400,000 Ordinary Shares

Up to 4,422,604 American Depositary Shares Representing 442,260,400,000 Ordinary Shares Underlying the Pre-Funded Warrants

Up to 8,845,208 American Depositary Shares Representing 884,520,800,000 Ordinary Shares Underlying the Series L Warrants

Up to 221,130 American Depositary Shares Representing 22,113,000,000 Ordinary Shares Underlying the Placement Agent Warrants

___________________</div>

This preliminary prospectus,
or prospectus, relates to a best efforts public offering of up to 4,422,604 Units, or Units, of Biodexa Pharmaceuticals PLC, a public
limited company organized under the laws of England and Wales, or the Company, each Unit consisting of (i) one American Depositary Share
(representing 100,000 of our ordinary shares, nominal value £0.000001 per share, or Ordinary Shares), or Depositary Shares, and
(ii) two Series L warrants, or Series L Warrants, each to purchase one Depositary Share, at an assumed combined public offering price
of $4.07 per Unit, based upon the closing price of our Depositary Shares on the NASDAQ Capital Market on December 9, 2025.

Each Series L Warrant
will be immediately exercisable at an exercise price of 100% of the public offering price of each Unit in this offering and will expire
five (5) years after the issuance date. The Series L Warrants also contain certain anti-dilution protections.

Please see the section of
this prospectus entitled “Description of the Securities we are Offering” for further information.

We are also offering the
opportunity to purchase, if the purchaser so chooses in lieu of Units, up to 4,422,604 pre-funded units, or the Pre-Funded Units, to
purchasers whose purchase of Units in this offering would otherwise result in the purchaser, together with its affiliates, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Ordinary Shares immediately following the consummation
of this offering. Each Pre-Funded Unit consists of (i) one pre-funded warrant exercisable for one Depositary Share, or a Pre-Funded Warrant,
and (